Insider trade

CEO sold ~$11.3M of JNJ shares in the open market

Traded Jan 26, 2026 · Filed Jan 28, 2026

Johnson & JohnsonJNJ

~$11.3M
Reported value · 51K sh @ $220.986: 80K
Holds after · shares reported: +16.8%
stock since the trade · S&P 500 +10.3%, $221.49 → $258.66 on Oct 1

Why it stands out

The boss of Johnson & Johnson sold $11.3M of Johnson & Johnson shares. Nobody planned it ahead of time.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Dates, kept separate

Transaction date: Jan 26, 2026
Reporting period: Not applicable
Filed with the SEC: Jan 28, 2026

CEOIndirect holding$1M+

Context

Classification

open market sale

Code S — open-market or private sale

Absolute commitment

~$11,318,461

Shares × reported transaction price

Timing vs results

5 days after results of Jan 21, 2026, 78 days before results of Apr 14, 2026

Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results

Price at the time

Closed at $221.49 on Jan 26, 2026, at its 52-week high, after a 7% rise over the previous 30 trading days

52-week range $146.36 (May 14, 2025) to $221.49 (Jan 26, 2026), 100% of the way up, from 251 adjusted closes. 30 trading days earlier: $206.54 on Dec 10, 2025. Describes the past only, not a forecast

Planned / mechanical clue

None found in footnotes

Only flagged when a footnote says so; never inferred

FDA decision near the trade

FDA approved Darzalex Faspro on Jan 27, 2026, 1 day after this trade.

New use approved (efficacy supplement). Active ingredient: Daratumumab and Hyaluronidase-Fihj. From openFDA. Dates only; no link between the two is implied

After it was reported

After	Stock	S&P 500	Difference
7 days	+4.6%	-2.4%	+7.0%
30 days	+9.4%	-1.1%	+10.5%
90 days	+0.0%	+2.5%	-2.5%
180 days	+17.4%	+6.8%	+10.6%

Past results only. Not a forecast.

Source receipt

Record ID: 0000200406-26-000004
Filed / recorded: Jan 28, 2026, 11:07 PM UTC
Added to OQRO: Oct 2, 2026, 3:52 AM UTC
Parser: form4-xml-v1
Data quality: Verified: identifiers matched exactly
Issuer: JOHNSON & JOHNSON
Issuer CIK: 200406
Ticker: JNJ
Reporting person: Joaquin Duato
Relationship: Director, Officer
Officer title: CEO and Chairman of the Board
Security: Common Stock
Table: Non-derivative (Table I)
Transaction date: Jan 26, 2026
Transaction code: S
Shares / units: 51,218
Price per share: $220.986
Acquired / disposed: Disposed (D)
Shares owned after: 79,634
Ownership form: Indirect — By spouse
Amendment: No

Footnotes from the filing

This transaction was executed in multiple trades at prices ranging from $220.39 to $221.376. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request, to the SEC staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.